曲妥珠单抗与化疗治疗晚期乳腺癌的效果观察及不良反应发生率影响评价

Effect of trastuzumab and chemotherapy on advanced breast cancer and evaluation of the incidence of adverse reactions

目的探究曲妥珠单抗与化疗治疗晚期乳腺癌的效果观察及不良反应发生率影响。方法本院选择2017年11月至2018年10月收治的90例晚期乳腺癌患者作为本次研究对象,并且针对患者给予不同的治疗方法,将患者分为观察组和对照组,各45例,对照组应用单纯的化疗进行治疗,观察组采用化疗联合曲妥珠单抗方式进行治疗。比较两组患者在治疗效果以及不良反应发生情况。结果观察组的治疗效果要比对照组更加有效,不良反应发生情况方面低于对照组,两组差异具有统计学意义(P<0.05)。结论曲妥珠单抗与化疗治疗晚期乳腺癌的效果观察及不良反应发生率影响效果显著,能够为今后的相关研究提供借鉴。

Objective To investigate the effect of trastuzumab and chemotherapy on advanced breast cancer and the incidence of adverse reactions. Methods 90 patients with advanced breast cancer admitted to our hospital from November 2017 to October 2018 were selected as the subjects of this study, and different treatment methods were given to the patients. The patients were divided into observation group and control group, 45 cases in each group. The control group was treated with chemotherapy alone. The observation group was treated with chemotherapy combined with trastuzumab. The difference between the two groups of patients in the treatment effect and the occurrence of adverse reactions was compared. Results The therapeutic effect of the observation group was more effective than that of the control group. The incidence of adverse reactions was lower than that of the control group, and the difference between the two groups was significant (P<0.05). Conclusion The effect and significance of trastuzumab and chemotherapy in the treatment of advanced breast cancer are important, and it is guaranteed to provide reference for future research.